



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tamtuvetmab

Cat. No.:	HY-P99579
CAS No.:	1608122-71-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tamtuvetmab (AT-005) is a caninised blontuvmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary ^{[1][2]} .	
IC₅₀ & Target	CD52 ^[1]	
In Vivo	Tamtuvetmab (5 mg/mL, 7.5-30 mL; i.v.; 15-30 min) has in vivo efficacy in dogs with naïve T-cell lymphoma (LSA), but resulting in vomiting, weight loss, diarrhoea, lethargy, decreased appetite and anorexia ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	T-cell LSA Model in Dog ^[1]
	Dosage:	5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL
	Administration:	Intravenous injection; 15-30 min
	Result:	Showed in vivo efficacy with severe side effect.

REFERENCES

- [1]. Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. *Vet Rec Open*. 2022 Nov 1;9(1):e49.
- [2]. Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. *Theriogenology*. 2018 May;112:75-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA